Chengdu Easton Biopharmaceuticals (688513.SS) Earnings Analysis
Chengdu Easton Biopharmaceuticals (688513.SS) has no confirmed upcoming earnings date. Trailing P/E 33.20.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 688513.SS next report earnings?
No confirmed upcoming earnings date is currently scheduled for 688513.SS. This page updates as the calendar is published.
688513.SS earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-02-27 | 0.38 CNY | n/a | n/a | n/a |
| 2025-10-27 | 0.4794 CNY | n/a | n/a | n/a |
| 2025-04-25 | 0.34 CNY | n/a | n/a | n/a |
| 2025-02-27 | 0.12 CNY | n/a | n/a | n/a |
| 2024-10-24 | 0.402 CNY | n/a | n/a | n/a |
| 2024-08-19 | 0.2772 CNY | n/a | n/a | n/a |
688513.SS valuation and analyst view
| Trailing P/E | 33.20 |
|---|---|
| Trailing EPS | 1.573 CNY |
| Price / book | 3.06 |
| Dividend yield | 0.93% |
| Market cap | 9.52B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Chengdu Easton Biopharmaceuticals (688513.SS)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for 688513.SS. This page updates as the calendar is published.
Did 688513.SS beat earnings last quarter?
Consensus estimate data was not available for 688513.SS's 2026-02-27 report.
What is 688513.SS's current P/E ratio and EPS?
688513.SS trades at a trailing P/E of 33.20 on trailing EPS of 1.573246182125667 CNY.
What do analysts rate 688513.SS?
688513.SS has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.